Emapalumab-Izsg
Phase 2Small molecule
Emapalumab-Izsg is one of 52 small molecule programs targeting Sepsis. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
51
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
308 competitors in Sepsis
#DrugCompanyPhaseTrials
1Corlanor
AmgenPreclinical
Simdax
Orion Corporation, Orion PharmaPreclinical
Zemplar
AbbViePreclinical
Primaxin
PfizerPreclinical
Brevibloc
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Levophed
GGeneral Hospital of Ningxia Medical University
Preclinical
Emapalumab-Izsg
NNational Institute of Allergy and Infectious Diseases (NIAID)
Phase 2
Jardiance
Boehringer IngelheimPreclinical
Micardis
Boehringer IngelheimPreclinical
Achromycin V
WWyeth-Lederle Vaccines
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sepsis1 trial
Chronic Granulomatous Disease1 trial
Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists
Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT05463133·50 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Emapalumab-Izsg. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details